- Home
- LFST vs ARQT Comparison
LFST vs ARQT Comparison
Compare LFST & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- ARQT
- Stock Information
- Founded
- LFST 2015
- ARQT 2016
- Country
- LFST United States
- ARQT United States
- Employees
- LFST N/A
- ARQT N/A
- Industry
- LFST Medical/Nursing Services
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- LFST Health Care
- ARQT Health Care
- Exchange
- LFST Nasdaq
- ARQT Nasdaq
- Market Cap
- LFST 2.1B
- ARQT 2.1B
- IPO Year
- LFST 2021
- ARQT 2020
- Fundamental
- Price
- LFST $5.37
- ARQT $17.71
- Analyst Decision
- LFST Strong Buy
- ARQT Strong Buy
- Analyst Count
- LFST 5
- ARQT 7
- Target Price
- LFST $8.60
- ARQT $19.00
- AVG Volume (30 Days)
- LFST 2.0M
- ARQT 1.6M
- Earning Date
- LFST 11-06-2025
- ARQT 11-05-2025
- Dividend Yield
- LFST N/A
- ARQT N/A
- EPS Growth
- LFST N/A
- ARQT N/A
- EPS
- LFST N/A
- ARQT N/A
- Revenue
- LFST $1,316,483,000.00
- ARQT $263,464,999.00
- Revenue This Year
- LFST $15.27
- ARQT $72.46
- Revenue Next Year
- LFST $14.29
- ARQT $31.69
- P/E Ratio
- LFST N/A
- ARQT N/A
- Revenue Growth
- LFST 13.86
- ARQT 99.50
- 52 Week Low
- LFST $3.74
- ARQT $8.03
- 52 Week High
- LFST $8.61
- ARQT $18.15
- Technical
- Relative Strength Index (RSI)
- LFST 54.72
- ARQT 63.97
- Support Level
- LFST $5.11
- ARQT $16.62
- Resistance Level
- LFST $5.40
- ARQT $18.15
- Average True Range (ATR)
- LFST 0.21
- ARQT 0.69
- MACD
- LFST -0.06
- ARQT 0.03
- Stochastic Oscillator
- LFST 46.43
- ARQT 85.57
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.